<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04727788</url>
  </required_header>
  <id_info>
    <org_study_id>VDX 20-1001</org_study_id>
    <nct_id>NCT04727788</nct_id>
  </id_info>
  <brief_title>Validation of Genomic Immune-phenotyping Profiles to Predict Risk of Kidney Transplant Rejection</brief_title>
  <official_title>Validation of Genomic Immune-phenotyping Profiles in Peripheral Blood Gene Signatures to Predict Risk of Kidney Transplant Rejection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verici Dx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verici Dx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Global, non-randomized, observational study for the validation of Verici Dx genomic tests to&#xD;
      predict risk of kidney clinical and subclinical acute rejection, and chronic allograft damage&#xD;
      or interstitial fibrosis / tubular atrophy by correlating peripheral blood gene expression&#xD;
      profiles with graft injury (e.g. cellular / antibody-mediated), rejection and death censored&#xD;
      graft loss.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is correlative and observational and will involve collecting clinical and&#xD;
      pathological data along with blood, biopsy tissue and urine during standard routine scheduled&#xD;
      medical visits for transplant preparation or monitoring. The blood will be used for next&#xD;
      generation sequencing in the Verici Dx laboratory to create transcriptomic profiles to&#xD;
      validate performance characteristics of three Verici Dx sequencing immune-phenotype signature&#xD;
      risk score tests. The research biopsy tissue and urine are for secondary or exploratory&#xD;
      objectives. To allow comparison with current accepted standard approaches to identify kidney&#xD;
      transplant injury or rejection, digital images of stained tissue sections taken from&#xD;
      surveillance or for-cause biopsy tissue will be evaluated in a central pathology laboratory&#xD;
      for the purposes of this study. Enrolled subjects will continue in the study for 24 months&#xD;
      during which the planned validation of the acute clinical and subclinical rejection tests&#xD;
      will complete after 6 months of follow-up; subjects will be followed to 24 months for the&#xD;
      validation of the Verici Dx blood-based fibrosis risk prognostic test. After 24 months,&#xD;
      patients will be followed through ANZDATA and UNOS registry data for later development of&#xD;
      fibrosis or for graft loss or death.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pre-transplant: test for prediction of risk of Early Acute Rejection (EAR)</measure>
    <time_frame>baseline</time_frame>
    <description>early acute rejection occurring within first 6 months, including borderline ACR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute Cellular Rejection (ACR): test to identify the risk of clinical and sub-clinical ACR</measure>
    <time_frame>6 months</time_frame>
    <description>clinical or subclinical acute rejection 3 months post transplant including borderline ACR, acute cell-mediated rejection as confirmed by histologic evidence on biopsy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fibrosis: test to predict the risk of developing fibrosis of the allograft and allograft loss</measure>
    <time_frame>24 months</time_frame>
    <description>clinical or subclinical acute rejection due to fibrosis 12 months post transplant as confirmed by histologic evidence on biopsy</description>
  </primary_outcome>
  <enrollment type="Anticipated">414</enrollment>
  <condition>Kidney Transplant Rejection</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, urine, tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Kidney or kidney/pancreas transplant patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Individual Recipients of living or deceased donor kidney transplant&#xD;
&#xD;
          2. Age: ≥ 18 ≤ 80&#xD;
&#xD;
          3. The subject must be able to comprehend and sign an approved informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recipients of multiple organ transplant, except kidney-pancreas multiple transplant&#xD;
&#xD;
          2. Subjects who are currently participating in a therapeutic clinical trial for&#xD;
             transplant rejection&#xD;
&#xD;
          3. HIV or Hepatitis C positive patients&#xD;
&#xD;
          4. Persons who are known to be pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J Donovan, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Verici Dx</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angela Rose</last_name>
    <phone>9196673507</phone>
    <email>arose@vericidx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Benken, Pharm-D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Gallon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Maluf, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milagros Samaniego, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roslyn Mannon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Augustine, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saed Shawar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolae Leca, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble Alpes Health Center</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel Rostaing, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bologna University</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaetano LaManna</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brescia University</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Alberici</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Vall d'Hebron, Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oriol Bestard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paramit Chowdhury</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Theodoros Kasimatis</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 22, 2021</study_first_submitted>
  <study_first_submitted_qc>January 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

